PRIMAPRED 20MG CP BOITE DE 10
PRIMAPRED 20MG CP BOITE DE 10 A

PRIMAPRED 20MG CP BOX OF 10

Conditions or diseases: collagenosis, connectivities: Progressive outbreaks of systemic diseases, in particular: systemic lupus erythematosus, vasculitis, polymyositis, visceral sarcoidosis. Dermatological: Severe autoimmune bullous dermatosis, in particular pemphigus and bullous pemphigoid. Severe forms of angiomas in infancy. Certain forms of lichen planus. Some acute urticaria. Severe forms of neutrophilic dermatosis. Digestive: Progressive outbreaks of ulcerative colitis and Crohn’s disease. Autoimmune chronic active hepatitis (with or without cirrhosis). Histologically proven severe acute alcoholic hepatitis. Endocrine: Subacute severe de Quervain thyroiditis. Certain hypercalcemia. Hematologic: Severe immunologic thrombocytopenic purpura. Autoimmune hemolytic anemias. In combination with various chemotherapies in the treatment of lymphoid malignant hemopathies. Chronic acquired or congenital erythroblastopenia. Infectious: Tuberculous pericarditis and severe, life-threatening forms of tuberculosis. Pneumocystis carinii pneumonia with severe hypoxia. Neoplastic: Antiemetic treatment during antineoplastic chemotherapy. Edematous and inflammatory flare associated with antineoplastic treatments (radio and chemotherapy). Nephrological: Nephrotic syndrome with minimal glomerular lesions. Nephrotic syndrome of primary segmental and focal hyalinosis. Stages III and IV of lupus nephropathy. Intrarenal granulomatous sarcoidosis. Vasculitis with renal involvement. Primary extra capillary glomerulonephritis. Neurological: Myasthenia gravis. Cerebral edema of tumor cause. Chronic, idiopathic, inflammatory polyradiculoneuritis. Infantile spasm (West syndrome), Lennox-Gastaut syndrome. Multiple sclerosis in a flare, after intravenous corticosteroid therapy. Ophthalmologic: Severe anterior and posterior uveitis. Edematous exophthalmos. Certain optic neuropathies, in the relay of intravenous corticosteroid therapy (in this indication, the first-line oral route is not recommended). ENT: Certain serious ear infections. Nasosinus polyposis. Certain acute or chronic sinusitis. Short-term seasonal allergic rhinitis. Acute stridular laryngitis (subglottic laryngitis) in children. Respiratory: Persistent asthma preferably as a short course in the event of failure of inhaled treatment at high doses. Asthma exacerbations, especially severe acute asthma. Chronic obstructive pulmonary disease in evaluation of the reversibility of obstructive syndrome. Progressive sarcoidosis. Diffuse interstitial pulmonary fibrosis. Rheumatologic: Rheumatoid arthritis and certain polyarthritis. Rhizomelic pseudo polyarthritis and Horton’s disease. Acute articular rhumatism. Severe and rebellious cervicobrachial neuralgia. Allogeneic hematopoietic organ and stem cell transplantation: Prophylaxis or treatment of transplant rejection. Prophylaxis or treatment of graft versus host reaction.

 

Category:

Additional information

Specialty

Dosage

Form

Presentation

Primary packaging

Specification

, ,

DCI

Classement VEIC

Therapeutic class

Sub Class

Laboratory

CHART

The duration of the conversation

Generic / Princeps

AMM

Date AMM

Range

,